Ustekinumab as the First Biological Agent for Treatment of Crohn's Disease with Growth Failure and Arrest of Puberty: A Pediatric Case
Year: 2023
Type: article
Study design: Case Report
Abstract: A 14-year-old boy diagnosed with Crohn's disease, complicated by growth failure, arrest of puberty, and perianal abscess, was treated with ustekinumab. We observed improvements in the endoscopic and histological gastrointestinal tract pathology, growth failure, arrest of puberty, and bone mineral density. Crohn's disease can affect both growth and the development of secondary sexual characteristics and bone mineral density; thus, treatment should be selected for both the gastrointestinal tract pathology and the aforementioned factors. Few reports have shown the effectiveness of ustekinumab as the first biological agent for the treatment of pediatric Crohn's disease. In this pediatric case with growth failure and arrest of puberty, ustekinumab as the first biological agent was both effective and safe.
Institution: Dokkyo Medical University
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7208058355